



RONALD M. BUKOWSKI, MD, EDITOR

From the Editor

THE DIAGNOSIS and treatment of neoplastic diseases is a rapidly evolving discipline. Progress in the field of biotechnology, including recombinant cytokines and monoclonal antibodies, has contributed to advancement in the therapy and diagnosis of these disorders. In view of these rapid changes, guidelines addressing current therapeutic management of various malignancies are necessary.

This *Cleveland Clinic Journal of Medicine* supplement is the first in a series of management guidelines for neoplastic diseases. Doctors Fisher and Oken have reviewed the non-Hodgkin's lymphomas to define practice guidelines for the diagnosis and treatment of this diverse group of tumors.

Future supplements will focus on such topics as renal cell carcinoma, melanoma, superficial bladder cancer, and multiple myeloma. The goal is to develop treatment plans that will permit cancer care

providers to improve patient outcomes while containing health care costs. Each of the therapeutic management guidelines will be developed as a free-standing Continuing Medical Education publication. The objective of these supplements, and of other educational commitments intended for the near future, is to share up-to-date information crucial to our understanding of the diagnosis and therapy of the targeted cancers.

We hope you find this supplement to be of value. Please let us know your comments and suggestions; we would appreciate hearing from you.

RONALD M. BUKOWSKI, MD
Cleveland Clinic Cancer Center